


1. (Original) A compound having the structure of Formula I



Formula I

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides

wherein

m is an integer from 0-2;

**R<sub>1</sub>** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl, or heterocyclalkyl;

**R<sub>2</sub>** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocycl, heteroarylalkyl, or heterocyclalkyl;

**R<sub>1</sub>** and **R<sub>2</sub>** may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, aryloxy, halogen (F, Cl, Br, I), aryl, aralkyl, heteroaryl, heterocycl, heteroarylalkyl or heterocyclalkyl;

**R<sub>3</sub>** can be NH<sub>2</sub>, NHOH, NHOR (wherein R can be alkyl, alkenyl, alkynyl, cycloalkyl or aralkyl), or OR<sub>m</sub> (wherein R<sub>m</sub> can be hydrogen, alkyl, aralkyl, aryl, or metal ions ( Na<sup>+</sup>, K<sup>+</sup>, Li<sup>+</sup>, Ca<sup>+</sup> or Mg<sup>+</sup> ));

**R<sub>4</sub>** can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocycl, heteroarylalkyl, heterocyclalkyl, -(CH<sub>2</sub>)<sub>1-4</sub>-O-R' (wherein R' can be selected from the group

consisting of hydrogen, alkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclalkyl, or heteroarylalkyl),  $-C(=O)-R_3$  (wherein  $R_3$  is the same as defined above)  $-C(=O)R_z$  (wherein  $R_z$  is  $-NR_7R_8$  wherein  $R_7$  and  $R_8$  can be independently selected from hydrogen (provided that both  $R_7$  and  $R_8$  are not hydrogen, represented as "amino"), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclalkyl, heteroarylalkyl, heterocyclalkyl,  $SO_2R_9$  (wherein  $R_9$  can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclalkyl, heteroaryl, heteroarylalkyl, heterocyclalkyl); or  $R_7$  and  $R_8$  may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclalkyl, heteroarylalkyl, or heterocyclalkyl; or  $(CH_2)_{1-4}NR_xR_y$  [wherein  $R_x$  and  $R_y$  can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclalkyl, heterocyclalkyl, heteroarylalkyl,  $-YR_u$  (wherein Y is C(=O), C(=S) or  $SO_2$  and  $R_u$  is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclalkyl, heterocyclalkyl or heteroarylalkyl),  $-C(=T)NR_u$  (wherein T is oxygen, sulphur,  $-CH(NO_2)$ ,  $-N(NO_2)$  or  $-N(CN)$  and  $R_u$  is the same as defined above) or  $-C(=O)OR_u$  (wherein  $R_u$  is the same as defined above)];

$R_5$  and  $R_6$  may be independently selected from hydrogen, alkyl, cycloalkyl, heterocyclalkyl, heteroarylalkyl, heterocyclalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring.

2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)

7. (Cancelled)
8. (Original) A compound according to claim 1, wherein R<sub>2</sub> is optionally substituted aralkyl.
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Original) A compound according to claim 1, wherein R<sub>2</sub> is heteroarylalkyl.
17. (Cancelled)
18. (Original) A compound according to claim 1, wherein R<sub>2</sub> is aryl.
19. (Cancelled)
20. (Original) A compound according to claim 1, wherein R<sub>1</sub> and R<sub>2</sub> may also together join to form cyclic ring (3-8 membered), optionally benzofused containing 0-4 heteroatoms O, S or N.
21. (Cancelled)
22. (Original) A compound according to claim 1, wherein R<sub>3</sub> is -OR<sub>m</sub> or -NH<sub>2</sub>.
23. (Cancelled)
24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Original) A compound according to claim 22, wherein R<sub>3</sub> is -NH<sub>2</sub>.

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (Cancelled)

45. (Cancelled)

46. (Cancelled)

47. (Cancelled)

48. (Cancelled)

49. (Cancelled)

50. (Cancelled)

51. (Cancelled)

52. (Cancelled)

53. (Cancelled)

54. (Cancelled)

55. (Cancelled)

56. (Cancelled)

57. (Cancelled)

58. (Cancelled)

59. (Original) A compound of claim 1, wherein  $R_4$  is  $-C(=O)R_3$ .

60. (Cancelled)

61. (Cancelled)

62. (Cancelled)

- 63. (Cancelled)
- 64. (Cancelled)
- 65. (Original) A compound of claim 1, wherein R<sub>5</sub> is hydrogen, alkyl or aryl.
- 66. (Cancelled)
- 67. (Cancelled)
- 68. (Cancelled)
- 69. (Cancelled)
- 70. (Cancelled)
- 71. A compound of claim 1, wherein R<sub>6</sub> is hydrogen.
- 72. (Cancelled)
- 73. (Cancelled)
- 74. (Cancelled)
- 75. (Cancelled)
- 76. (Cancelled)
- 77. (Original) A compound selected from

(S)-2-{{{(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-(4-hydroxy-phenyl)-propionic acid (Compound No. 1),

(S)-2-{{{(4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 2),

(S)-3-(4-Benzoylamino-phenyl)-2-{{{(4R,5R)-5-(2-chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 3),

(S)-3-(4-Hydroxy-phenyl)-2- {[ (4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 4),

(S)-2- {[ (4R,5R)-5-(2-Methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 5),

(S)-3-[4-(2,6-difluoro-benzyloxy)phenyl]-2- {[ (4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]-dioxolane-4-carbonyl]-amino}-propionic acid (Compound no. 6),

(S)-3-(4-Benzoylamino-phenyl)-2- {[ (4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 7),

(S)-2- {[ (4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 8),

(S)-2- {[ (4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 9),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2- {[ (4R,5R)-5-(2-methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No.10),

Lithium salt of (S)-2- {[ (4R,5R)-5-(2-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No.11),

Lithium salt of (S)-2- {[ (4R,5R)-5-(2-Methoxy-benzyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(3-piperidin-1-yl-propoxy)-phenyl]-propionate (Compound No. 12),

Lithium salt of (S)-2- {[ (4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-propionate (Compound No. 13),

(S)-2- {[ (4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]-propionic acid (Compound No. 14),

Morpholine-4-carboxylic acid 4-((S)-2- {[ (4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenyl ester (Compound No. 15),

4-Methyl-piperazine-1-carboxylic acid 4-((S)-2- {[ (4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-2-carboxy-ethyl)-phenylester (Compound No. 16),

(S)-2- {[ (4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 17),

(S)-2- {[ (4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(2,6-dichloro-pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 18),

- (S)-2-{{{(4R,5R)-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-[(piperidine-4-carbonyl)-amino]-phenyl]}-propionic-acid, salt with trifluoroacetic acid (Compound No.19),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-[(pyridine-3-carbonyl)-amino]-phenyl]}-propionic acid (Compound No. 20),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-[(pyridine-2-carbonyl)-amino]-phenyl]}-propionic-acid (Compound No. 21),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-[6-bromo-pyridine-2-carbonyl)-amino]-phenyl]}-propionic acid (Compound No. 22),
- (S)-3-(4-Benzoylamino-phenyl)-2-{{{(4R,5R)-5-(biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 23),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-(4-hydroxyl-phenyl)}-propionic acid (Compound No. 24),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 25),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2-chloro-benzyloxy)-phenyl]}-propionic-acid (Compound No. 26),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-(4-prop-2-ynyloxy-phenyl)}-propionic-acid (Compound No. 27),
- (S)-3-{4-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{{{(4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 28),
- (S)-2-{{{(4R,5R)-5-(Biphenyl-2-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2-methoxy-benzyl-amino)-phenyl]}-propionic acid (Compound No 29),
- (S)-2-{{{(4R,5R)-5-(3,5-Dichlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-difluoro-benzyloxy)-phenyl]}-propionic-acid (Compound No. 30),
- (S)-3-{4-(2,6-Dichlorobenzyloxy)-phenyl}-2-{{{(4R,5R)-5-[thiophen-2-yl-methyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 31),
- (S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-phenyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (compound no 32),
- (S)-2-{{{(4S,5S)-5-(2-Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-[(pyridin-4-carbonyl)-amino]-phenyl]}-propionic acid (Compound No 33),



(S)-2-[[{(4S,5S)-5-(Chlorophenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichlorobenzoyloxy-phenyl)]-propionic acid (Compound No.34),

(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichlorobenzoyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carboxylic acid (Compound No. 35),

Lithium salt of (S)-2-[[{(4R,5R)-5-Cyclopropyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichlorobenzoyloxy)-phenyl]-propionate (Compound No. 36),

(S)-2-[[{(4R,5R)-5-Cyclohexane-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzoyloxy)-phenyl]-propionic acid (Compound No 37) ,

(S)-3-[4-(2,6-Dichlorobenzoyloxy)-phenyl]-2-[[{(4R,5R)-5-(thiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 38) ,

(S)-2-[[{(4R,5R)-5-(Cyclopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No 39) ,

(S)-2-[[{(4R,5R)-5-Cyclohexyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic acid (Compound No. 40),

(S)-2-[[{(4R,5R)-5-(3,5-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbamoyl]-amino}-3-{4-[(pyridine-4-carbonyl-amino)-phenyl]-propionic acid (Compound No. 41) ,

(4R,5R)-5-[(S)-1-Carboxy-2-[4-(hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 42) ,

(S)-3-(4-benzoylaminophenyl)-2-[[{(4R,5R)-5-(isopropyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 43),

(S)-3-[4-(2,6-Dichloro-benzoyloxy)-phenyl]-2-[[{(4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid salt with trifluoroacetic acid (Compound No 44),

(S)-2-[[{(4R,5R)-5-(2,6-Dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-{4-[(pyridine-4-carbonyl)-amino]-phenyl}-propionic-acid (Compound No. 45),

(4R,5R)-5-[(S)-Carboxy-2-[4-(2,6-dichlorobenzoyloxy)-phenyl]-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid ethyl ester (Compound No. 46),

(S)-3-[4-(2,6-Dichloro-benzoyloxy)-phenyl]-2-[[{(4R,5R)-5-isopropylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No.47),

(S)-2-[[{(4R,5R)-5-tert-Butyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzoyloxy)-phenyl]-propionic acid (Compound No. 48),

(S)-3-[4-(2,6-Dichloro-benzyloxy-phenyl)-2-{{(4R,5R)-5-(3-methyl-butylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 49),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(R)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 50),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(S)-1-phenyl-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 51),

(S)-1-{{(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichlorobenzyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-pyrrolidine-2-carboxylic acid benzyl ester(Compound No. 52),

(S)-2-{{(4R,5R)-5-(Benzothiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.53),

(S)-2-[(4R,5R)-{5-Benzyloxy-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 54),

(S)-3-[4-2-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(morpholine-4-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No.55),

(S)-2-(((4R,5R)-{5-allyl-carbamoyl-[1,3]dioxolane-4-carbonyl}-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 56),

1-{{(4R,5R)-5-[(S)-1-Carboxy-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-pyrrolidine-2-carboxylic acid (Compound No.57),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(tetrahydro-furan-2-yl-methyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 58),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[2-(1H-indol-3-yl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 59),

(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(2-thiophen-2-yl-ethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 60),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-[(pyridin-4-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No.61),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(2,3-dihydro-indole-1-carbonyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 62),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{(4R,5R)-5-(5-methyl-[1,3,4]thiadiazol-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No.63),

(S)-2-[[{(4R,5R)-5-(Biphenyl-2-yl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(4-hydroxyphenyl)-propionic acid (Compound No. 64),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-(methyl-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No.65),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[4R,5R)-5-[methyl-(1-methyl-piperidine-4-yl)-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 66),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-(2-fluoro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 67),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-(2-methoxy-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 68),

(S)-2-[[{(4R,5R)-5-(4-Chloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No.69),

(S)-2-[[{(4R,5R)-5-(3-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 70),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-(3,5-dichloro-phenyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic-acid (Compound No.71),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[4R,5R)-5-(2,6-dichlorophenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 72),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-O-tolyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound no.73),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-dimethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No. 74),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-methyl-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic acid (Compound No.75),

(S)-3-[4-[(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-methoxy-carbamoyl-[1,3]dioxolane-4-carbonyl]-amino]-propionic-acid (Compound No. 76),

(4R,5R)-5-[(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichlorobenzyloxy-phenyl)-ethylcarbamoyl]-[1,3]dioxolane-4-carboxylic acid (Compound No.77),

(S)-2,3-[4(2,6-Dichloro-benzyloxy)-phenyl]-2-[[{(4R,5R)-5-[2-(4-hydroxy-phenyl)-ethyl-carbamoyl]-[1,3]dioxolane-4-carbonyl]-amino]-propionic-acid (Compound No. 78),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(pyrrolidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 79),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(R)-3-hydroxy-pyrrolidine-1-carbonyl]-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 80),

1-((4R,5R)-5-{(S)-1-tert-Butoxycarbonyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethylcarbamoyl}-[1,3]dioxolane-4-carbonyl)-pyrrolidine-2-carboxylic acid (Compound No. 81),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(1-hydroxymethyl-propylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 82),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-ethylcarbamoyl]-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 83),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-prop-2-ynylcarbamoyl]-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 84),

Trifluoroacetate salt of (S)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(2-morpholin-4-yl-ethylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 85),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 86),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 87),

(S)-2-[[ (4R,5R)-5-(Bis-thiophen-2-ylmethyl-carbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 88),

(S)-2-[[ (4R,5R)-5-(Bicyclo[2.2.1]hept-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 89),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(2,6-diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 90)

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(2-isopropyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 91),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-[[ (4R,5R)-5-(2,6-difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 92),

(S)-2-[[ (4R,5R)-5-(2,6-Difluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino]-3-(4-(pyridine-4-carbonyl)-amino)-phenyl}-propionic acid (Compound No. 93),

(S)-2-{{{(4R,5R)-5-(2,6-Diethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-(4-[(pyridine-4-carbonyl)-amino]-phenyl)}-propionic acid (Compound No. 94),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5S)-5-hydroxymethyl-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 95),

(S)-2-{{{(4R,5R)-5-Carbamoyl-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 96),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-((R)-2-hydrox-1-phenyl-ethylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 97),

(S)-2-{{{(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-phenyl-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 98),

(S)-2-{{{(4R,5R)-5-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 99),

(S)-2-{{{(4R,5R)-5-(2-sec-Butyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 100),

(S)-2-{{{(4R,5R)-5-Benzyloxymethyl-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 101),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-(2-trifluoromethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 102),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-(2-isopropoxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 103),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-(4-hydroxy-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 104),

(S)-2-{{{(4R,5R)-5-Cyclopentylcarbamoyl-[1,3]dioxolane-4-carbonyl}-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]}-propionic acid (Compound No. 105),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-hexylcarbamoyl-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 106),

(S)-3-[4-(2,6-Dichlorobenzyloxy)-phenyl]-2-{{{(4R,5R)-5-(3,4-dimethyl-isoxazol-5-ylcarbamoyl)-[1,3]-dioxolane-4-carbonyl}amino-propionic acid (Compound No. 107),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{{{(4R,5R)-5-(pyridin-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl}-amino}-propionic acid (Compound No. 108),

{2-[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolone-4-carbonyl]-1,2,3,4-tetrahydro-isoquinoline}-3-carboxylic acid (Compound No. 109),

2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-(1H-indol-3-yl)-propionic acid (Compound No. 110),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 111),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(morpholin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 112),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2-methyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 113),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4-hydroxy-cyclohexylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 114),

(S)-2-{[(4R,5R)-5-(2-Chloro-phenylcarbamoyl)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 115),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-heptylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 116),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(2-ethyl-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 117),

(4R,5R)-[1,3]Dioxolane-4,5-dicarboxylic acid-4-({(S)-1-carbamoyl-2-[4-(2,6-dichloro-benzyloxy)-phenyl]-ethyl}-amide)-5-[(2-chloro-phenyl)-amide] (Compound No. 118),

(S)-2-{[(4R,5R)-5-(2-Benzyl-5-tert-butyl-2H-pyrazol-3-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 119),

(S)-2-{[(4R,5R)-5-cycloheptylcarbamoyl-[1,3]dioxolane-4-carbonyl]-amino}-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 120),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(5-ethylsulphanyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 121),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(S)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 122),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-{[(4R,5R)-5-(4,5-dimethylthiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 123),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((R)-2,2-dimethyl-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 124),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5R)-5-(4-oxo-piperidine-1-carbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 125),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5R)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl)-methyl-amino)-propionic acid (Compound No. 126),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5R)-5-(indan-5-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 127),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5R)-5-phenethylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 128),

(S)-2-(((4R,5R)-5-[(Benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 129),

(S)-2-(((4R,5R)-5-Butylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 130),

(S)-2-(((4R,5R)-5-(4-Acetyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 131),

(S)-2-(((4R,5R)-5-(2-Cyclopentyloxy-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 132),

(S)-2-(((4R,5R)-5-(2-Cyclopentyloxy-5-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzyloxy)-phenyl]-propionic acid (Compound No. 133),

3-Benzo[1,3]dioxol-5-yl-3-(((4R,5R)-5-(2-chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 134),

(S)-2-(((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-(2-methoxy-biphenyl-4-yl)-propionic acid (Compound No. 135),

(S)-2-(((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-(4-fluoro-phenyl)-propionic acid (Compound No. 136),

(S)-2-(((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-(2,6-dimethoxy-biphenyl-4-yl)-propionic acid (Compound No. 137),

(S)-3-(((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 138),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5R)-5-octylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 139),

3-(((4R,5R)-5-(2-Chloro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-(3,4-dimethoxy-benzyl)-amino)-propionic acid (Compound No. 140),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5S)-5-methoxymethyl-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 141),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5R)-5-(3,5-dichloro-pyridin-4-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 142),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(2-fluoro-phenylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 143),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-[2-(1H-indol-3-yl)-ethylcarbamoyl]-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 144),

(S)-2-(((4R,5R)-5-Cyclohexylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 145),

Trifluoroacetate salt of (S)-3-[4-(2,6-Dichlorobezylxy)-phenyl]-2-(((4R,5S)-5-pyrrolidin-1-ylmethyl-[1,3]Dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 146),

(S)-2-(((4R,5R)-5-(Biphenyl-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 147),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-[(thiophen-2-ylmethyl)-carbamoyl]-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 148),

(S)-3-[4-(2,6-Dichloro-benzyloxy)-phenyl]-2-(((4R,5S)-2,2,5-trimethyl-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 149),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(thiazol-2-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 150),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(2-methoxy-benzylcarbamoyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 151),

(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-(((4R,5R)-5-(4-methyl-piperazine-1-carbonyl)-[1,3]dioxolane-4-carbonyl)-amino)-propionic acid (Compound No. 152),

(S)-2-(((4R,5R)-5-Cyclopropylcarbamoyl-[1,3]dioxolane-4-carbonyl)-amino)-3-[4-(2,6-dichloro-benzoylamino)-phenyl]-propionic acid (Compound No. 153), and



(S)-3-[4-(2,6-Dichloro-benzoylamino)-phenyl]-2-{{[(4R,5R)-5-(piperidin-1-ylcarbamoyl)-[1,3]dioxolane-4-carbonyl]-amino}-propionic acid (Compound No. 154).

78. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 together with pharmaceutically acceptable carrier, excipients or diluents.


79. (Original) A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable excipient.

80. (Original) A method of preventing, inhibiting or suppressing inflammatory condition in an animal or human comprising administering to said animal or human a therapeutically effective amount of a compound according to claim 1.



81. (Original) A method of treating an animal or human suffering from cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis in an animal or human comprising administering to said animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 79.

82. (Original) A method of preventing, inhibiting or suppressing inflammatory disease in an animal or human comprising administering to said animal or human a therapeutically effective amount of the pharmaceutical composition according to claim 78.



83. (Currently Amended) A method of preparing a compound of Formula XVI




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises hydrolyzing a compound of Formula II to yield a compound of Formula III;




condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;




hydrolyzing the compound of Formula V to yield a compound of Formula VI;




condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl);




reducing the compound of Formula VIII to yield a compound of Formula XIII


(when R<sub>2</sub> is );



reacting the compound of Formula XIII with a compound of Formula XIV to yield a compound of Formula XV; and



hydrolyzing the compound of Formula XIV to yield a compound of Formula XVI,




wherein

wherein  $R_7$  and  $R_8$  are independently selected from hydrogen (provided that both  $R_7$  and  $R_8$  are not hydrogen, represented as “amino”), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl,  $SO_2R_9$ , (wherein  $R_9$  can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or  $R_7$  and  $R_8$  may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or  $(CH_2)_{1-4}NR_xR_y$  [wherein  $R_x$  and  $R_y$  can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl,  $-YR_u$  (wherein Y is C(=O), C(=S) or  $SO_2$  and  $R_u$  is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl),  $-C(=T)NR_u$  (wherein T is oxygen, sulphur,  $-CH(NO_2)$ ,  $-N(NO_2)$  or  $-N(CN)$  and  $R_u$  is the same as defined above) or  $-C(=O)OR_u$  (wherein  $R_u$  is the same as defined above)];

$R_5$  and  $R_6$  are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring; and

$R_9$  is selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl.


85. (Currently Amended) A method of preparing a compound of Formula XII




Formula XII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein said method comprises:

hydrolyzing a compound of Formula II to yield a compound of Formula III;




Formula II




Formula III

condensing the compound of Formula III with a compound of Formula IV to yield a compound of Formula V;




Formula IV




Formula V

hydrolyzing the compound of Formula V to yield a compound of Formula VI;



Formula VI


condensing the compound of Formula VI with a compound of Formula VII to yield a compound of Formula VIII (wherein P is methyl, ethyl t-butyl or benzyl); and



Formula VII

Formula VIII

hydrolyzing the compound of Formula VIII is ~~hydrolyzed~~ to yield a compound of Formula XII,



Formula XII

wherein


wherein R<sub>7</sub> and R<sub>8</sub> are independently selected from hydrogen (provided that both R<sub>7</sub> and R<sub>8</sub> are not hydrogen, represented as “amino”), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, SO<sub>2</sub>R<sub>9</sub> (wherein R<sub>9</sub> can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclalkyl); or R<sub>7</sub> and R<sub>8</sub> may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino,

substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl; or  $(CH_2)_{1-4}NR_xR_y$  [wherein  $R_x$  and  $R_y$  are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl, heteroarylalkyl,  $-YR_u$  (wherein Y is C(=O), C(=S) or  $SO_2$  and  $R_u$  is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl or heteroarylalkyl),  $-C(=T)NR_u$  (wherein T is oxygen, sulphur,  $-CH(NO_2)$ ,  $-N(NO_2)$  or  $-N(CN)$  and  $R_u$  is the same as defined above) or  $-C(=O)OR_u$  (wherein  $R_u$  is the same as defined above)]; and

$R_5$  and  $R_6$  are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring.




86. (Cancelled)

87. (Currently Amended) A method for preparing a compound of Formula XXI




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:


condensing a compound of Formula III with a compound of Formula XVII to yield a compound of Formula XVIII;



hydrolyzing the compound of Formula XVIII to yield a compound of Formula XXII; and



condensing the compound of Formula XXIII with a compound of Formula IV to yield a compound of Formula XXI,



wherein

R<sub>2</sub> is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R<sub>7</sub> and R<sub>8</sub> are independently selected from hydrogen (provided that both R<sub>7</sub> and R<sub>8</sub> are not hydrogen, represented as “amino”), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO<sub>2</sub>R<sub>9</sub> (wherein R<sub>9</sub> is selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R<sub>7</sub> and R<sub>8</sub> may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or (CH<sub>2</sub>)<sub>1-4</sub>NR<sub>x</sub>R<sub>y</sub> [wherein R<sub>x</sub> and R<sub>y</sub> are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, -YR<sub>u</sub> (wherein Y is C(=O), C(=S) or SO<sub>2</sub> and R<sub>u</sub>




is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl or heteroarylalkyl),  $-C(=T)NR_u$  (wherein T is oxygen, sulphur,  $-CH(NO_2)$ ,  $-N(NO_2)$  or  $-N(CN)$  and  $R_u$  is the same as defined above) or  $-C(=O)OR_u$  (wherein  $R_u$  is the same as defined above)];

$R_5$  and  $R_6$  are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring; and

wherein P is methyl, ethyl t-butyl or benzyl.

88. (Cancelled)


89. (Currently Amended) A method for preparation of compound of Formula XXVII



Formula XXVII


its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

reducing the compound of Formula XXV




Formula XXV

to yield a compound of Formula XXVI (wherein  $P_1$  is ethyl, t-butyl, or benzyl); and



Formula XXVI

hydrolyzing the compound of Formula XXVI to furnish a compound of Formula XXVII,




Formula XXVII

wherein

$R_2$  is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; and

$R_5$  and  $R_6$  are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring.


90. (Currently Amended) A method for preparation of compound of Formula XXIII



Formula XXIII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:


reducing the compound of Formula XXV



Formula XXV


to yield a compound of Formula XXVI (wherein P<sub>1</sub> is ethyl, t-butyl, or benzyl); and

reacting the compound of Formula XXVI with a compound of Formula R<sub>m</sub>-hal to yield a compound of Formula XXVIII; and



Formula XXVIII

hydrolyzing the compound of Formula XXVIII to yield a compound of Formula XXXIII,



Formula XXXIII

wherein

m is an integer from 0-2;


R<sub>2</sub> is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl;

R<sub>5</sub> and R<sub>6</sub> are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, aryl, or aralkyl; or R<sub>5</sub> and R<sub>6</sub> may together join to form a cycloalkyl ring; and

R<sub>m</sub> is hydrogen, alkyl, aralkyl, aryl, or metal ion.


91. (Cancelled)

92. (Currently Amended) A method for preparation of compound of Formula XXXII




its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:


reducing the compound of Formula XXV




to yield a compound of Formula XXVI (wherein P<sub>1</sub> is ethyl, t-butyl, or benzyl); and  
 reacting the compound of Formula XXVI with a compound of Formula L-hal to yield a  
 compound of Formula XXX;



condensing the compound of Formula XXX with a compound of Formula IV (wherein OL is a  
 leaving group selected from, mesyl or tosyl) to yield a compound of Formula XXXI; and



hydrolyzing the compound of Formula XXXI to yield a compound of Formula XXXII,




wherein

R<sub>2</sub> is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R<sub>5</sub> and R<sub>6</sub> are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R<sub>5</sub> and R<sub>6</sub> may together join to form a cycloalkyl ring; and

R<sub>7</sub> and R<sub>8</sub> are independently selected from hydrogen (provided that both R<sub>7</sub> and R<sub>8</sub> are not hydrogen, represented as “amino”), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO<sub>2</sub>R<sub>9</sub> (wherein R<sub>9</sub> can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R<sub>7</sub> and R<sub>8</sub> may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or (CH<sub>2</sub>)<sub>1-4</sub>NR<sub>x</sub>R<sub>y</sub> [wherein R<sub>x</sub> and R<sub>y</sub> can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, -YR<sub>u</sub> (wherein Y is C(=O), C(=S) or SO<sub>2</sub> and R<sub>u</sub> is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), -C(=T)NR<sub>u</sub> (wherein T is oxygen, sulphur, -CH(NO<sub>2</sub>), -N(NO<sub>2</sub>) or -N(CN) and R<sub>u</sub> is the same as defined above) or -C(=O)OR<sub>u</sub> (wherein R<sub>u</sub> is the same as defined above)].



93. (Currently Amended) A method for the preparation of the compound of Formula XXXVIII




Formula XXXVIII

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

hydrolyzing a compound of Formula XXXV to yield a compound of Formula XXXVI;




reacting the compound of Formula XXXVI with a compound of Formula VII to yield a compound of Formula XXXVII; and



hydrolyzing the compound of Formula XXXIII to yield a compound of Formula XXXVIII,  
wherein  $R_1$  is H or  $CH_3$ ; P is methyl, ethyl, t-butyl or benzyl;  $R_2$  is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; and  $R_5$  and  $R_6$  are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or  $R_5$  and  $R_6$  may together join to form a cycloalkyl ring;

R<sub>7</sub> and R<sub>8</sub> are independently selected from hydrogen (provided that both R<sub>7</sub> and R<sub>8</sub> are not hydrogen, represented as “amino”), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclalkyl, SO<sub>2</sub>R<sub>9</sub> (wherein R<sub>9</sub> can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclalkyl); or R<sub>7</sub> and R<sub>8</sub> may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl; or (CH<sub>2</sub>)<sub>1-4</sub>NR<sub>x</sub>R<sub>y</sub> [wherein R<sub>x</sub> and R<sub>y</sub> can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl, heteroarylalkyl, -YR<sub>u</sub> (wherein Y is C(=O), C(=S) or SO<sub>2</sub> and R<sub>u</sub> is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclalkyl or heteroarylalkyl), -C(=T)NR<sub>u</sub> (wherein T is oxygen, sulphur, -CH(NO<sub>2</sub>), -N(NO<sub>2</sub>) or -N(CN) and R<sub>u</sub> is the same as defined above) or -C(=O)OR<sub>u</sub> (wherein R<sub>u</sub> is the same as defined above)].

94. (Currently Amended) A method for the preparation of the compound of Formula XL





Formula XL

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, polymorphs or N-oxides wherein the method comprises:

condensing a compound of Formula VI with a compound of Formula XXXIX





to yield a compound of Formula XL,

wherein


R<sub>2</sub> is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carboxy, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl;

R<sub>7</sub> and R<sub>8</sub> are independently selected from hydrogen (provided that both R<sub>7</sub> and R<sub>8</sub> are not hydrogen, represented as “amino”), alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, hydroxyalkyl, aralkyloxy, aryl, heteroaryl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, SO<sub>2</sub>R<sub>9</sub> (wherein R<sub>9</sub> can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, aryl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl); or R<sub>7</sub> and R<sub>8</sub> may together join to form a cyclic ring (3-8 membered), which may be optionally benzofused, containing 0-4 heteroatoms such as O, S, or N, wherein the rings may be substituted with one or more of alkyl, alkenyl, alkynyl, amino, substituted amino, cycloalkyl, carboxy, alkoxy, hydroxy, oxo, aryloxy, aryl, halogen (F, Cl, Br, I), aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; or (CH<sub>2</sub>)<sub>1-4</sub>NR<sub>x</sub>R<sub>y</sub> [wherein R<sub>x</sub> and R<sub>y</sub> can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl, -YR<sub>u</sub> (wherein Y is C(=O), C(=S) or SO<sub>2</sub> and R<sub>u</sub> is alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl), -C(=T)NR<sub>u</sub> (wherein T is oxygen, sulphur, -CH(NO<sub>2</sub>), -N(NO<sub>2</sub>) or -N(CN) and R<sub>u</sub> is the same as defined above) or -C(=O)OR<sub>u</sub> (wherein R<sub>u</sub> is the same as defined above)]; and

R<sub>5</sub> and R<sub>6</sub> are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclyl, heteroarylalkyl, heterocyclylalkyl, aryl, or aralkyl; or R<sub>5</sub> and R<sub>6</sub> may together join to form a cycloalkyl ring.

95. (Original) A compound of claim 1, wherein

$R_1$  is hydrogen;

$R_2$  is ;

$R_3$  is  $-\text{OH}$ ;

$R_4$  is  $-\text{C}(=\text{O})R_z$ ;

$R_5$  is hydrogen;

$R_6$  is hydrogen; and


$m$  is 0, wherein  $W$  is H, OH,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -aryl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -heteroaryl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -aryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -heterosaryl,  $\text{OCO}-(\text{CH}_2)_{0-3}$ -substituted aryl,  $\text{O}-(\text{CH}_2)_{0-3}$ -heterocyclyl,  $-\text{O}-(\text{CH}_2)_{0-3}$ -substituted heterocyclyl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -heterocyclyl,  $\text{NHCO}-(\text{CH}_2)_{0-3}$ -substituted heterocyclyl,  $\text{O}-(\text{CH}_2)_{0-3}$ -alkynyl,  $\text{O}-(\text{CH}_2)_{0-3}$ -alkenyl, or halogen.

96. (Original) The compound of claim 95, wherein  $R_z$  is  $-\text{NH}-(\text{CH}_2)_{0-3}$ -aryl,  $-\text{NH}-(\text{CH}_2)_{0-2}$ -substituted aryl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -cycloalkyl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -heteroaryl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -heterocyclyl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -substituted cycloalkyl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -substituted heteroaryl,  $-\text{NH}-(\text{CH}_2)_{0-3}$ -substituted heterocyclyl, N-containing heterocyclyl, substituted N-containing heterocyclyl, NH-alkyl, NH-substituted alkyl and  $\text{NH}_2$ .

97. (Cancelled)

98. (Original) A compound of claim 1, wherein

$R_1$  is hydrogen;

$R_2$  is ;

$R_3$  is  $-\text{OR}_m$ ;

$R_5$  is hydrogen;

$R_6$  is hydrogen; and

$m$  is 0.

99. (Original) The compound of claim 98, wherein

$R_4$  is carboxyl,  $C_{1-4}$  alkyl ester, hydroxyl methyl,  $CH_2OCH_2-C_6H_5$ , or  $CH_2OCH_3$ .

100. (Original) The compound of claim 98, where  $R_m$  is hydrogen or  $C_1-C_5$  alkyl.

101. (Original) The compound of claim 98, herein W is H, OH,  $NHCO-(CH_2)_{0-3}$ -aryl,  $NHCO-(CH_2)_{0-3}$ -substituted aryl,  $NHCO-(CH_2)_{0-3}$ -heteroaryl,  $NHCO-(CH_2)_{0-3}$ -substituted aryl,  $OCO-(CH_2)_{0-3}$ -aryl,  $OCO-(CH_2)_{0-3}$ -substituted aryl,  $OCO-(CH_2)_{0-3}$ -heterosryl,  $OCO-(CH_2)_{0-3}$ -substituted aryl,  $O-(CH_2)_{0-3}$ -heterocyclyl,  $-O-(CH_2)_{0-3}$ -substituted heterocyclyl,  $NHCO-(CH_2)_{0-3}$ -heterocyclyl,  $NHCO-(CH_2)_{0-3}$ -substituted heterocyclyl,  $O-(CH_2)_{0-3}$ -alkynyl,  $O-(CH_2)_{0-3}$ -alkenyl, or halogen.

102. (Original) A compound of claim 1, wherein

$R_1$  is hydrogen or  $C_{1-5}$  alkyl;

$R_2$  is OH, or  $NH_2$ ;

$R_5$  is hydrogen;

$R_6$  is hydrogen; and

$m$  is 0.

103. (Original) The compound of claim 102, wherein

$R_4$  is  $CONH$ -aryl,  $CONH$ -substituted aryl, or  $(CH_2)_{1-3}-O-CH_3$ .